EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study

R C Wilson iD, M J Gilchrist iD, R Cele, S d'Arc, E A Mills, C Ndhlovu, B Balancio, P Arkell, L Read, M Bayliss, A R Noel, A P MacGowan und 2 weitere

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkaf484 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von R C Wilson und 13 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Antimicrobial Optimisation, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Drug Monitoring, Anti-Bacterial Agents, Ambulatory Care. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Imperial College Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Notwithstanding the wide uptake of outpatient antimicrobial therapy (OPAT) in the UK, there is a paucity of data on antimicrobial exposure. We aimed to assess antimicrobial pharmacokinetic–pharmacodynamics (PK–PD) for several agents in our service with a view to understanding a potential role for therapeutic drug monitoring (TDM) and precision antimicrobial therapy in this setting.

Methods

The study was a prospective, observational, pilot PK–PD study. Adult patients receiving intravenous ceftazidime, ceftriaxone, daptomycin, ertapenem, flucloxacillin or teicoplanin, or oral treatment with linezolid were enrolled. Peak and trough blood samples were obtained. Total and unbound antibacterial concentrations were measured. Clinical details, laboratory findings and UK OPAT good practice recommendation metrics were extracted from the medical record. PK–PD was interpreted according to EUCAST rationale documents and other published guidance. Doses were not adjusted except for linezolid and teicoplanin.

Results

In total, 39 patients were recruited to the study, predominantly on ceftriaxone (21/39, 54%) or ertapenem (6/39, 15%). Four patients received (10%) teicoplanin, three (8%) ceftazidime, three (8%) flucloxacillin, one (3%) linezolid and one (3%) daptomycin. The most common reason for OPAT was bacteraemia and endocarditis (6/39; 15% each). PK–PD target attainment was acceptable for all drugs and dose regimens, and all β-lactam-based treatments met conservative PK–PD targets.

Conclusions

We have demonstrated that drug monitoring is practicable in the OPAT setting of a large institution with no on-site analytical capability. Current dosage regimens result in acceptable PK–PD target attainment. Our findings provide an initial step towards supporting TDM in OPAT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug MonitoringAnti-Bacterial AgentsAmbulatory CareHumansProspective StudiesMaleMiddle AgedFemaleAgedAdultPilot ProjectsOutpatientsUnited KingdomAged, 80 and overBacterial InfectionsYoung Adult

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Centre for Antimicrobial Optimisation, Imperial College London, London, UK.
  • Pharmacy Department, Imperial College Healthcare NHS Trust, London, UK.
  • National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.
  • David Price Evans Infectious Diseases & Global Health Group, The University of Liverpool, Liverpool, UK.
  • OPAT Service, Imperial College Healthcare NHS Trust, London, UK.
  • Department of Infectious Disease, Imperial College London, Charing Cross Hospital Campus, London, UK.

ORCID-Profile: R C Wilson, M J Gilchrist

Förderung

  • Imperial College Healthcare

Zitieren

APA

Wilson, R. C., Gilchrist, M. J., Cele, R., d'Arc, S., Mills, E. A., Ndhlovu, C., Balancio, B., Arkell, P., Read, L., Bayliss, M., Noel, A. R., MacGowan, A. P., Holmes, A. H., & Rawson, T. M. (2026). Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf484

Vancouver

Wilson RC, Gilchrist MJ, Cele R, d'Arc S, Mills EA, Ndhlovu C, et al. Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf484

BibTeX
@article{Wilson2026,
  author = {Wilson, R C and Gilchrist, M J and Cele, R and d'Arc, S and Mills, E A and Ndhlovu, C and Balancio, B and Arkell, P and Read, L and Bayliss, M and Noel, A R and MacGowan, A P and Holmes, A H and Rawson, T M},
  title = {Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkaf484}
}
Kostenlos starten →